PGEN News and Press, Precigen Inc. From 11/22/23

2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...

2023-11-09 18:02:02 ET More on Precigen Precigen's Express Lane: Racing Towards RRP Remedies (Rating Upgrade) Precigen director increases holding by 25K shares Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Finan...

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs PR Newswire – Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission u...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Precigen Inc. (PGEN) is expected to report $-0.08 for Q3 2023

Precigen to Participate in the Stifel 2023 Healthcare Conference PR Newswire GERMANTOWN, Md. , Nov. 7, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to imp...

2023-09-26 12:36:38 ET More on Precigen Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial information for Precigen Precigen's Express Lane: Racing Towards RRP Remedies (Rating Upgrade) Precigen, Inc. (PGEN...

Precigen to Participate in Upcoming Leading Investor and Industry Conferences PR Newswire GERMANTOWN, Md. , Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell t...

2023-08-28 09:15:57 ET Summary Precigen, a clinical-stage biopharmaceutical company, shows potential with flagship drug PRGN-2012 for RRP, given accelerated FDA processes. Despite financial challenges, the company's shift to in-house gene therapy manufacturing and strategic financ...

2023-08-17 12:16:09 ET Engaging in the world of low-cost stocks often referred to as penny stocks , is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk. They’re also known for ...